Research

Hormonal

Tirzepatide at 15 mg and maximum tolerated dose (MTD) provides superior weight loss efficacy compared to semaglutide (2.4 mg and MTD) in non-diabetic adults with obesity, but this benefit is offset by significantly higher rates of gastrointestinal side effects and treatment discontinuation.

If you are a non-diabetic adult with obesity seeking maximum weight loss, tirzepatide at 15mg or MTD is statistically more effective than semaglutide. However, you must accept a higher risk of gastrointestinal side effects and a higher chance of stopping the medication due to those side effects. Discuss your tolerance for potential side effects versus the desire for maximum weight loss with your provider.

GoodQualifiesHIGH confidence
Tirzepatide at 15 mg and MTD offers the greatest efficacy for weight loss in non-diabetic adults with obesity, though at the cost of increased gastrointestinal side effects and higher discontinuation rates.
Alousious Kasagga et al. · Cureus · 2025

Why this rating

Network meta-analysis of 8 RCTs with 7,179 participants; high certainty for most interventions, though some heterogeneity exists.

Source

Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials

Alousious Kasagga et al. · Cureus · 2025

DOI 10.7759/cureus.90335

Meta-analysis · 8 studies
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →